Element Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Element Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,298	Closed	-$849K	–	971
2018 Q1	$849K	Buy	+45,298	New	+$739K	0.02%	225
2017 Q3	–	Sell	-22,994	Closed	-$175K	–	88
2017 Q2	$175K	Buy	+22,994	New	+$171K	0.04%	101

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Element Capital Management's RCKT Position: Q2 2018 in Review

Element Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2018, closing a stake of 45,298 shares — an estimated $849K sold.

Element Capital Management first reported a position in RCKT in Q2 2017 and held it in 2 quarters. The position peaked at $849K in Q1 2018. 76 funds tracked by Wall St. Rank hold RCKT as of Q2 2018.

Element Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Element Capital Management sold 45,298 Rocket Pharmaceuticals shares in Q2 2018, an estimated $849K.
Element Capital Management first reported a position in Rocket Pharmaceuticals in Q2 2017 and held it in 2 quarters.
Element Capital Management's Rocket Pharmaceuticals position peaked at $849K in Q1 2018.
76 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.